Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

In October 2024, Trevi Therapeutics company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

By Zach Montague Reporting from Washington President Trump signed an executive order on Tuesday taking steps to end gender-affirming medical treatments for children and teenagers under 19 ...

The successful use of inhaled morphine to relieve dyspnea in a patient with end-stage cystic fibrosis (CF ... decline in pulmonary function. The only treatment for end-stage CF lung disease ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Conclusion Exposure to ELF-MF represents a possible new approach for treatment of biofilm-associated cystic fibrosis lung infections. Physicians treating CF patients are increasingly faced with ...